Q-omics provides the consensus-scored PLAC8L1 profile across patient tissues and cancer cell-line models. PLAC8L1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PLAC8L1 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, PLAC8L1 RNA expression shows 15,589 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where PLAC8L1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLAC8L1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLAC8L1 survival associations across molecular data types. PLAC8L1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLAC8L1 RNA expression–survival associations across cancer types. High PLAC8L1 expression shows unfavorable associations in KIRC, COAD and KIRP, but favorable associations in PAAD, HNSC and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify KIRC as the clearest survival context for PLAC8L1 RNA expression.
This table summarizes PLAC8L1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PLAC8L1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLAC8L1 shows lower tumor expression in THCA and BRCA and higher tumor expression in KIRC, LIHC, LUSC and STAD. The KIRC box plot shows higher PLAC8L1 RNA expression in tumor versus normal tissue (log2 FC = +0.546, t-test p < 0.001).
This table shows molecular features associated with PLAC8L1 in patient tissues and cancer cell lines. In patient samples, PLAC8L1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PLAC8L1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_SCLC.
